Fig. 7: In vitro validation of PCNA as a therapeutic target for prostate cancer. | British Journal of Cancer

Fig. 7: In vitro validation of PCNA as a therapeutic target for prostate cancer.

From: Senescence-related gene signature predicts prostate cancer progression and identifies PCNA as a therapeutic target via multi-omics machine learning integration

Fig. 7: In vitro validation of PCNA as a therapeutic target for prostate cancer.

a CCK-8 assay demonstrating the effect of AOH1996 on the proliferation of PC3 and DU145 cells. Statistical method: two-sided unpaired t test. b Colony formation assays showing the influence of AOH1996 on the clonogenicity of PC3 and DU145 cells. Statistical method: two-sided unpaired t test. c Flow cytometry apoptosis analysis revealing the effect of AOH1996 on the proportions of apoptotic PC3 and DU145 cells. Statistical method: one way ANOVA followed by Dunnett’s test.

Back to article page